Erica Roberta Barbalho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Erica Roberta Barbalho has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Ana Paula Trussardi Fayh
Postgraduate Program in Health Sciences, Health Sciences Center, Federal University of Rio Grande Do Norte, Natal, Brazil
2 shared publications - Galtieri Otávio Cunha de Medeiros
Postgraduate Program in Health Sciences, Health Sciences Centre, Federal University of Rio Grande do Norte, Natal 59078-970, Brazil
2 shared publications - Ilanna Marques Gomes da Rocha
Laboratory of Nutrition and Metabolic Surgery (LIM-35), Department of Gastroenterology, Faculdade de Medicina, Hospital das Clinicas HCFMUSP, Universidade de São Paulo, São Paulo 13563-120, Brazil
2 shared publications - Aline Marcadenti
Hcor Research Institute, Hospital do Coracao, Sao Paulo 04004-030, Brazil
1 shared publication - Carlos Alves de Sousa Júnior
Universidade Federal do Rio Grande do Norte (UFRN), Brazil
1 shared publication - Ricardo Andrade Bezerra
Universidade Federal do Rio Grande do Norte
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Radiologia Brasileira
- Vol. 57, e20240012
The additional benefit of computed tomography in cancer patients: impacts of sarcopenia and cachexia on quality of life during chemotherapy
Objective: This study evaluates the effects of sarcopenia and cachexia on the quality of life (QoL) of patients with gastrointestinal cancer during their initial cycle of chemotherapy, emphasizing the significance of computed tomography (CT) in assessing muscle mass. Materials and Methods: In this prospective study, we evaluated 60 adult patients with gastrointestinal cancer who started chemotherapy between January and December of 2017. Sarcopenia was diagnosed on the basis of CT findings, and QoL was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Results: The mean age was 60.9 years, and 33 (55.0%) of the patients were men. Of the 60 patients, 33 (55.0%) had cachexia and 14 (23.3%) had sarcopenia. Chemotherapy significantly reduced QoL, particularly in the physical, role functioning, and social domains, with no differences between the cachexia and sarcopenia groups. Conclusion: Among patients with gastrointestinal cancer submitted to chemotherapy, the chemotherapy-induced decline in QoL does not seem to differ significantly between those with cachexia or sarcopenia, as classified by CT-measured muscle mass, and those without. However, CT-based muscle mass evaluation remains crucial for guiding customized intervention strategies. Integrating this evaluation in radiological reports can provide valuable insights for planning specific care, thus improving patient QoL during treatment.
- 1 January 2024
- Published by FapUNIFESP (SciELO) in Radiologia Brasileira
- Vol. 57, e20240012
Open AccessThe additional benefit of computed tomography in cancer patients: impacts of sarcopenia and cachexia on quality of life during chemotherapy
Objective: This study evaluates the effects of sarcopenia and cachexia on the quality of life (QoL) of patients with gastrointestinal cancer during their initial cycle of chemotherapy, emphasizing the significance of computed tomography (CT) in assessing muscle mass. Materials and Methods: In this prospective study, we evaluated 60 adult patients with gastrointestinal cancer who started chemotherapy between January and December of 2017. Sarcopenia was diagnosed on the basis of CT findings, and QoL was assessed with the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30. Results: The mean age was 60.9 years, and 33 (55.0%) of the patients were men. Of the 60 patients, 33 (55.0%) had cachexia and 14 (23.3%) had sarcopenia. Chemotherapy significantly reduced QoL, particularly in the physical, role functioning, and social domains, with no differences between the cachexia and sarcopenia groups. Conclusion: Among patients with gastrointestinal cancer submitted to chemotherapy, the chemotherapy-induced decline in QoL does not seem to differ significantly between those with cachexia or sarcopenia, as classified by CT-measured muscle mass, and those without. However, CT-based muscle mass evaluation remains crucial for guiding customized intervention strategies. Integrating this evaluation in radiological reports can provide valuable insights for planning specific care, thus improving patient QoL during treatment.
- Open Access
- 25 September 2019
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 64 (AHEAD) , 24-29
Agreement between software programmes of body composition analyses on abdominal computed tomography scans of obese adults
Key words: Body composition; skeletal muscle mass; subcutaneous adipose tissue; visceral fat; imaging techniques
- 25 September 2019
- Published by Archives of Endocrinology and Metabolism in Archives of Endocrinology and Metabolism
- Vol. 64 (AHEAD) , 24-29
Open AccessAgreement between software programmes of body composition analyses on abdominal computed tomography scans of obese adults
Key words: Body composition; skeletal muscle mass; subcutaneous adipose tissue; visceral fat; imaging techniques